Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Lantheus Holdings has suddenly become one of the more closely watched names in healthcare M&A after reports that Curium Pharma made a takeover offer valuing the radiopharmaceutical company at about $7 billion.</li><li>The news pushed Lantheus shares higher and gave investors a fresh reason to look beyond the stock’s recent operating debates.</li><li>This is not just a simple buyout rumor.</li></ul>

Lantheus Holdings has suddenly become one of the more closely watched names in healthcare M&A after reports that Curium Pharma made a takeover offer valuing the radiopharmaceutical company at about $7 billion.The news pushed Lantheus shares higher and gave investors a fresh reason to look beyond the stock’s recent operating debates.This is not just a simple buyout rumor.

Lantheus Holdings Just Became The $7 Billion Radiopharma Target Everyone Is Watching!

Smartkarma's AI Co-Pilot, Smartkarma

αSK

Smartkarma's AI Co-Pilot

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<ul>
  <li>Lantheus is a leader in the radiopharmaceutical and diagnostic imaging market, with its blockbuster prostate cancer imaging agent, PYLARIFY, being the primary revenue driver.</li>
  <li>The company is strategically diversifying its portfolio through acquisitions, notably in the Alzheimer's disease diagnostic space with NeuraCeq, and is advancing a pipeline of radiodiagnostic and radiotherapeutic assets to fuel future growth.</li>
  <li>While demonstrating strong historical growth, the company faces significant risks from increasing competition for PYLARIFY, pricing pressures, and the execution risk associated with integrating new assets and transitioning to new product formulations.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  Lantheus is a leader in the radiopharmaceutical and diagnostic imaging market, with its blockbuster prostate cancer imaging agent, PYLARIFY, being the primary revenue driver.
  The company is strategically diversifying its portfolio through acquisitions, notably in the Alzheimer's disease diagnostic space with NeuraCeq, and is advancing a pipeline of radiodiagnostic and radiotherapeutic assets to fuel future growth.
  While demonstrating strong historical growth, the company faces significant risks from increasing competition for PYLARIFY, pricing pressures, and the execution risk associated with integrating new assets and transitioning to new product formulations.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Lantheus Holdings (LNTH US) - May 2026

Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

<ul><li>Zacks Small-Cap Research Note for Lantheus Holdings, Inc. (LNTH)</li></ul>

Zacks Small-Cap Research Note for Lantheus Holdings, Inc. (LNTH)

<ul><li>Lantheus is a leader in radiopharmaceutical offerings in oncology & precision diagnostics.</li><li>It offers a portfolio of diagnostic & therapeutic products directly & via partnerships & licensing.</li><li>The primary revenue driver is Pylarify, a PET tracer for PSMA-expressing prostate cancer.</li></ul>

Lantheus is a leader in radiopharmaceutical offerings in oncology & precision diagnostics.It offers a portfolio of diagnostic & therapeutic products directly & via partnerships & licensing.The primary revenue driver is Pylarify, a PET tracer for PSMA-expressing prostate cancer.

United States

Lantheus Holdings, Inc. develops, manufactures, sells, and distributes diagnostic medical imaging agents and products. The Company offers imaging agents and products that assist clinicians in the diagnosis of cardiovascular and other diseases. Lantheus Holdings serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Lantheus Holdings (LNTH US)

Lantheus Holdings Just Became The $7 Billion Radiopharma Target Everyone Is Watching!

Lantheus Holdings has suddenly become one of the more closely watched names in healthcare M&A after reports that Curium Pharma made a takeover...

Baptista Research

Primer: Lantheus Holdings (LNTH US) - May 2026

Lantheus is a leader in the radiopharmaceutical and diagnostic imaging market, with its blockbuster prostate cancer imaging agent, PYLARIFY,...

αSK

LNTH: 1Q:26 Flash Report

Zacks Small-Cap Research Note for Lantheus Holdings, Inc. (LNTH)

Zacks Small Cap Research

LNTH: 2025 Earnings Flash Report

Zacks Small-Cap Research Note for Lantheus Holdings, Inc. (LNTH)

Zacks Small Cap Research

LNTH: Lantheus Closes SPECT Sale

Lantheus is a leader in radiopharmaceutical offerings in oncology & precision diagnostics. It offers a portfolio of diagnostic &...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)